Some really cool work we've been doing @oliolabs.bsky.social. New science opens the door to better medicines.

bioRxivpreprint@biorxivpreprint.bsky.social · last yr.

Sex differences in GLP-1 signaling across species https://www.biorxiv.org/content/10.1101/2025.03.17.643822v1

Check out what we're working on at Olio Labs! 70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men. What is driving this difference? We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out: